CEPR - Center for Economic and Policy Research

Multimedia

En Español

Em Português

Other Languages

Home Publications Reports Stagnation in the Drug Development Process: Are Patents the Problem?

Stagnation in the Drug Development Process: Are Patents the Problem?

March 2007, Dean Baker

The rate of new drug development has stagnated, in spite of large increases in both private and public sector spending on biomedical research. The flip side of slower progress is higher drug costs. The cost of developing new drugs has been rising at an average real rate of more than 7 percent since 1987. This report considers the ways in which government patent monopolies distort incentives so that pharmaceutical companies may not opt to minimize research costs. It documents some of the perverse incentives created by patent monopolies in drugs.

Report pdf_small

 

CEPR.net
donate_new
Combined Federal Campaign #79613